ANZCTR search results

As many as 1 in 4 Australians experience chronic pain. There is a critical need for the development and evaluation of fast-acting non-pharmaceutical treatments that have the capacity to target the multidimensional nature of chronic pain. This study will investigate how beliefs or expectations about the effects of mindfulness meditation interact with the actual effects of training in the technique, and will further characterise the mechanisms underlying these effects. Results will ultimately lead to targeted interventions that more effectively engage cognitive mechanisms associated with pain attenuation.

This study will evaluate the safety and performance of the Instylla Hydrogel Embolic System for patients requiring vascular embolisation alone or vascular embolisation for treatment of Malignant and Benign Hypervascular Tumors or non-traumatic end-organ infarct Who is it for? You may be eligible to join this study if you are aged 18 and above and are requiring vascular embolisation alone or vascular embolisation for treatment of Malignant and, or Benign Hypervascular Tumors, or non-traumatic end-organ infarct. Study details All participants will receive vascular embolisation using the Instylla Hydrogel Embolic System (HES) including Instylla Delivery Kit and Instylla Microcatheter. Safety and performance of the HES will be assessed using using the grading of the NCI Common Terminology Criteria for Adverse Events (CTCAE Version 5.0). Severity of complications will be further classified in accordance with Society of Interventional Radiology (SIR) guidelines. for up to 90 days post-embolisation. This study will also allow a greater understanding of whether HES can be used to embolise vascular tumours or organs.

The main purpose of this trial is to see whether the S-Check App can motivate behavioural change in those who use methamphetamine. The S-Check App has been developed as a harm reduction and early intervention tool It provides information on methamphetamine use and provides information on support services. One group will be randomised to have immediate access to the App for 28 days. The other group will have have access to the App after 28 days (delayed access). Both group at baseline (Day 0) will be asked to complete the Readiness to Change, General Help-Seeking and Actual Help-Seeking questionnaires. Those given immediate access to the App will repeat the survey at 28 days. Those given delayed access will repeat the survey before access is given. Both groups will also be asked to participate in a telephone interview to capture their experience using the App. App usage metrics will also be collected. The information collected will assist to further develop the App as a self-administered tool for those who use methamphetamine but do not wish seek traditional modes of treatment.

Aims: To improve identification and management of patients with ACS within rural hospitals in a Local Health District by implementing a hub and spoke ACS management system. MORACS clinicians will receive notification of patients presenting to intervention Hospitals with ACS symptoms, review ECG, troponin, clinical information and contact the site to provide advice on evidence based treatment. Research Question: In patients admitted to a rural hospital with suspected Acute Coronary Syndrome (ACS), does a centralised management system improve identification of STEMI and subsequent clinical outcomes in all ACS patients?

High dose magnesium administered intravenously is often utilized in the management of atrial fibrillation with a fast heart rate. Randomised controlled trials have shown conflicting results in regards to its efficacy. We aim to further examine the relationship between the heart rate and magnesium therapy in patients presenting to a Melbourne based Emergency Department with 'fast' atrial fibrillation. We are primarily interested in finding out whether Magnesium therapy aids the reduction of heart rate and our secondary endpoints include; reversion to sinus (normal) rhythm, time to achieve target heart rate, number of additional treatments required to achieve heart rate target, length of stay in emergency department, rate of inpatient hospital admission and 30 day mortality and readmission rates.

Dexmedetomidine is a drug that is commonly used on Intensive Care Units across the world in patients requiring sedation as part of their medical treatment. This research aims to see if this drug is protecting or causing harm to the kidneys. We will do this by using very sensitive techniques that detect kidney function, which are not used in routine clinical practice. There have been a few studies looking at this drug in the past, mainly with people undergoing heart operations. There have also been some studies looking at animals being given this drug for sedation. The results of these have been mixed, meaning that it is unclear what the true effect is of dexmedetomidine on the kidneys. This study hopes to look at a small number of patients who are already receiving this drug as part of their treatment and see what happens to their kidney function after they start receiving it.

Evaluating the effectiveness of the coach education program for sporting coaches. The program centers around positive coaching to create engaging learning environments for players whilst increasing the active playing time for participants

This study will evaluate the feasibility and acceptability of implementing a nurse-led screening assessment for older adults with cancer Who is it for? You may be eligible to join this study if you are aged 65 years or older, have been diagnosed with cancer and attend one of the cancer clinics who are implementing the screening assessments into routine practice. Study details All cancer clinics will start in the control arm and transition to intervention arm, but the order in which they transition will be allocated randomly (i.e. by chance). During the control arm period older people with cancer attending the clinic will have clinical assessments as decided by the multidisciplinary cancer treatment team. The intervention arm will receive a screening assessment administered by the cancer nurse to assess for mobility, self-rated health, appetite or weight changes and psychological concerns, Further comprehensive geriatric assessment may also be administered if needed to assess physical function, weight, nutritional status, cognition, other medical conditions, medication, and psychosocial wellbeing.

The aim of this controlled clinical trial was to test whether implant supported restorations have similar biological and technical outcomes when placed into previously augmented maxillary sinuses via the lateral wall approach using stabilized anorganic bovine bone mineral, as used in defined clinical scenarios (i.e. reduced local autogenous bone availability and/or sinus membrane perforation), when compared to those placed into a composite graft of anorganic bovine bone mineral and autogenous bone.

NF1 is a common genetic condition with a prevalence rate of at least 1 in 2,700 live births. While not diagnostic of the condition, cognitive and behavioural impairments are the most commonly cited childhood complications of NF1. NF1 is also highly comorbid with ADHD (40%) and autism spectrum disorders (ASD; 25%). Auditory Processing Disorder (APD) is characterised by abnormal auditory nerve function in the presence of normal functioning cochlear sensory hair cells. Common impairments include a reduced ability to perceive rapid changes in auditory signals (e.g., brief gaps or amplitude fluctuations) and speech perception difficulties in the presence of background noise, even at signal to noise ratios that would be expected in everyday listening environments (e.g., classrooms; playgrounds). Our recent phenotyping study of 36 NF1 individuals indicated that a significant proportion presented with convincing evidence of APD, compared to age matched healthy control participants. The children in our study who demonstrated clinically impaired performances on two or more tests of auditory processing, on average, also scored within the clinical range on parental questionnaires of inattentive ADHD symptoms. The clinical question that remains is whether auditory processing deficits in NF1 children can be treated. Intervention research suggests that assistive listening devices (ALD) attenuate speech processing deficits associated with APD in the general population. While there is evidence that ALD can improve listening and educational outcomes in other hearing-impaired populations, these systems have not yet been explored as an intervention option for children with NF1. The current clinical trial is a pilot study assessing all elements of the study design (recruitment strategy, tolerability of the study product, study duration, study procedures and outcome measures) to assess whether ALDs are acceptable and feasible for the conduct of a full-scale randomized clinical trial to treat auditory processing deficits in NF1 children. Eligible participants will have their hearing assessed under two conditions (with and without ALD) and testing order will be randomised. They will then be randomised to one of two treatment sequences: 1) being fitted with an inactive ALD for two weeks, followed by active ALD use for two weeks or 2) being fitted with an activated ALD for two weeks, followed by a period of two weeks of use with an inactivated ALD. We hypothesise that children will exhibit improved hearing outcomes while wearing the active ALD, as measured by an objective audiology assessment, and by questionnaire ratings from children, their parents and teachers.